Stockscreener 앱 받기
20.22
0.80%
0.16
Sarepta Therapeutics Inc 주식(SRPT)의 최신 뉴스
Jim Cramer on Sarepta Therapeutics: "If it Goes Up, You Gotta Do Some Selling" - Yahoo Finance
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
SRPT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
2025-08-20 | Lost Money on Sarepta Therapeutics, Inc. (SRPT)? Contact Levi & Korsinsky Before August 25, 2025 to Join Class Action | NDAQ:SRPT | Press Release - Stockhouse
SRPT Investors Have the Opportunity to Lead the Sarepta - GlobeNewswire
SRPT Investors Have the Opportunity to Lead the Sarepta Therapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Morningstar
BofA Securities Adjusts Price Target on Sarepta Therapeutics to $17 From $10, Maintains Underperform Rating - MarketScreener
What MACD and RSI say about Sarepta Therapeutics Inc.Profit Target & Risk Controlled Swing Alerts - Newser
Will Sarepta Therapeutics Inc. bounce back from current supportWeekly Risk Summary & Fast Exit/Entry Strategy Plans - Newser
Precision Trading with Sarepta Therapeutics Inc. (SRPT) Risk Zones - news.stocktradersdaily.com
Sarepta Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Sarepta Therapeutics, Inc. (SRPT) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of August 25, 2025 Deadline - Barchart.com
Sarepta Therapeutics, Inc. Class Action: Levi & Korsinsky - GlobeNewswire
Earnings visualization tools for Sarepta Therapeutics Inc.2025 EndofYear Setup & Intraday High Probability Alerts - Newser
Burned by Sarepta Therapeutics, Inc.? Contact Levi & Korsinsky to SueWallSt and Fight Back - ACCESS Newswire
SRPT’s Stock Dilemma: Sarepta Therapeutics Inc’s Market Performance and Outlook - investchronicle.com
Shareholders that lost money on Sarepta Therapeutics, Inc.(SRPT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
SRPT SECURITIES: Sarepta Therapeutics, Inc. Shareholders - GlobeNewswire
Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System - Defense World
PNC Financial Services Group Inc. Has $149,000 Stock Holdings in Sarepta Therapeutics, Inc. $SRPT - Defense World
Sarepta Therapeutics Inc. stock daily chart insightsJuly 2025 Trade Ideas & Safe Swing Trade Setup Alerts - Newser
Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) Over Securities ViolationsContact Levi & Korsinsky Today - ACCESS Newswire
Robbins LLP Reminds Sarepta Therapeutics, Inc. Stockholders - GlobeNewswire
Contact The Gross Law Firm by August 25, 2025 Deadline to - GlobeNewswire
Arrowhead (ARWR) Climbs 24.9% on $100-Million Licensing Revenue - Yahoo Finance
Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff - GlobeNewswire
Investors in Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Newsfile
Investors In Sarepta Therapeutics, Inc. (SRPT): Protect Your RightsContact Levi & Korsinsky Before August 25, 2025 - Barchart.com
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Sarepta Therapeutics, Inc.(SRPT) Shareholders - Morningstar
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
SRPT LOSSES: Sarepta Therapeutics, Inc. Investors with Losses are Encouraged to Contact BFA Law before Expiration of August 25 Class Action Deadline - Newsfile
How the Moms and Dads of Patients Won Sarepta’s Drug a Reprieve - Bloomberg.com
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP - GlobeNewswire
Will Sarepta Therapeutics Inc. outperform the marketPortfolio Update Summary & Pattern Based Trade Signal System - Newser
Sarepta Therapeutics, Inc. $SRPT Shares Sold by LPL Financial LLC - Defense World
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with - GlobeNewswire
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities LawsuitContact the DJS Law Group Before the Final DeadlineSRPT - MarketScreener
How Sarepta Therapeutics Inc. (SRPT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
2025-08-17 | Securities Class Action Lawsuit Filed Against Sarepta Therapeutics, Inc. (SRPT)Levi & Korsinsky Represents Shareholders | NDAQ:SRPT | Press Release - Stockhouse
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSRPT - FinancialContent
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Deutsche Bank Aktiengesellschaft Analyst Says - Defense World
Sarepta Changes Course, Agrees to Pause Elevidys Shipments - MSN
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, - GlobeNewswire
Sarepta Therapeutics and the Biotech Litigation Landscape: Navigating Risk in a High-Stakes Sector - AInvest
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - GlobeNewswire
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds - GlobeNewswire
BFA Law Notifies SAREPTA THERAPEUTICS, INC. (SRPT) Investors to Contact the Firm before the Upcoming August 25 Securities Fraud Class Action Deadline - Newsfile
US Bancorp DE Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Defense World
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop - GlobeNewswire
Sarepta Therapeutics Faces Questions Over Its Key Gene Therapy - Finimize
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ - MarketScreener
SRPT Deadline: Rosen Law Firm Urges Sarepta Therapeutics, Inc. (NASDAQ: SRPT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - Business Wire
Sarepta Therapeutics (SRPT) Declines Again On EMA - GlobeNewswire
Sarepta Therapeutics Still Faces Elevidys Demand Uncertainty, Deutsche Bank Says - MarketScreener
Your Guide to the Sarepta Therapeutics, Inc. LawsuitA SueWallSt Podcast From Levi & Korsinsky - ACCESS Newswire
SRPT LAWSUIT ALERT: Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. InvestorsLead Plaintiff Deadline August 25, 2025 - Newsfile
Investors in Sarepta Therapeutics, Inc. Should Contact Levi & Korsinsky Before August 25, 2025 to Discuss Your RightsSRPT - PR Newswire
0.94%
1.72%
자본화:
|
볼륨(24시간):